Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm

Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms

(2013) J. A. Kennedy et al.   BLOOD

Prognostic Model to Identify Patients With Myelofibrosis at the Highest Risk of Transformation to Acute Myeloid Leukemia

(2013) Alfonso Quintás-Cardama et al.   Clinical Lymphoma Myeloma & Leukemia

Mutations and prognosis in primary myelofibrosis

(2013) A M Vannucchi et al.   LEUKEMIA

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

(2012) A. Eghtedar et al.   BLOOD

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome

(2012) S.-J. Zhang et al.   BLOOD

Improving Survival Trends in Primary Myelofibrosis: An International Study

(2012) Francisco Cervantes et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase

(2012) Chad Cherington et al.   LEUKEMIA RESEARCH

Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium

(2012) John Mascarenhas et al.   LEUKEMIA RESEARCH

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients

(2011) A. Tefferi et al.   BLOOD

Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival

(2011) R. Vaidya et al.   BLOOD

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

(2011) Magnus Björkholm et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

(2011) A Tefferi et al.   LEUKEMIA

Very poor outcome of leukemic transformation in myelofibrosis: a single center experience with 13 patients

(2011) Grzegorz Helbig et al.   LEUKEMIA & LYMPHOMA

p53 Lesions in Leukemic Transformation

(2011) Ashot Harutyunyan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients

(2010) P. Morel et al.   BLOOD

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)

(2010) S. Thepot et al.   BLOOD

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms

(2010) N. H. Thoennissen et al.   BLOOD

Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias

(2010) O. Abdel-Wahab et al.   CANCER RESEARCH

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms

(2010) R Jäger et al.   LEUKEMIA

Therapeutic options for patients with myelofibrosis in blast phase

(2010) John Mascarenhas et al.   LEUKEMIA RESEARCH

Myeloid blastic transformation of myeloproliferative neoplasms—A review of 112 cases

(2010) Syed J. Noor et al.   LEUKEMIA RESEARCH

Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms

(2010) Anthony Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Special Issues in Myeloproliferative Neoplasms

(2010) Tiziano Barbui et al.   Current Hematologic Malignancy Reports

AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms

(2009) Y. Ding et al.   BLOOD

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm

(2009) P. A. Beer et al.   BLOOD

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

(2009) F. Passamonti et al.   BLOOD

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

(2009) Constantine S. Tam et al.   JOURNAL OF CLINICAL ONCOLOGY

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms

(2008) C. S. Tam et al.   BLOOD

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD

Risk factors for leukemic transformation in patients with primary myelofibrosis

(2008) Jocelin Huang et al.   CANCER

AML transformation in 56 patients with Ph− MPD in two well defined populations

(2008) Khadija Abdulkarim et al.   EUROPEAN JOURNAL OF HAEMATOLOGY